Listed

Sunshine Biopharma Inc.: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 15, 2019 and accepted by EDGAR at Aug 15, 2019, 13:29 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$3.0kus-gaap:Revenues
Revenue6 months2019-01-01 to 2019-06-30$3.2kus-gaap:Revenues
Cost of revenue3 months2019-04-01 to 2019-06-30$1.5kus-gaap:CostOfRevenue
Cost of revenue6 months2019-01-01 to 2019-06-30$1.6kus-gaap:CostOfRevenue
Gross profit3 months2019-04-01 to 2019-06-30$1.6kus-gaap:GrossProfit
Gross profit6 months2019-01-01 to 2019-06-30$1.7kus-gaap:GrossProfit
Operating income3 months2019-04-01 to 2019-06-30−$66.2kus-gaap:OperatingIncomeLoss
Operating income6 months2019-01-01 to 2019-06-30−$188.4kus-gaap:OperatingIncomeLoss
Interest expense3 months2019-04-01 to 2019-06-30$18.3kus-gaap:InterestExpense
Interest expense6 months2019-01-01 to 2019-06-30$64.6kus-gaap:InterestExpense
Net income3 months2019-04-01 to 2019-06-30−$710.9kus-gaap:NetIncomeLoss
Net income6 months2019-01-01 to 2019-06-30−$913.4kus-gaap:NetIncomeLoss
Basic EPS3 months2019-04-01 to 2019-06-30−$0.01us-gaap:EarningsPerShareBasic
Basic EPS6 months2019-01-01 to 2019-06-30−$0.01us-gaap:EarningsPerShareBasic
Operating cash flow6 months2019-01-01 to 2019-06-30−$280.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2019-01-01 to 2019-06-30$485us-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2019-06-30$37.3kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$70.9kus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$109.4kus-gaap:Assets
Current liabilitiesAt period end2019-06-30$925.7kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-06-30$925.7kus-gaap:Liabilities
Shareholders' equityAt period end2019-06-30−$816.3kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001654954-19-009672. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.